Revelation Biosciences Reports $3.3 Million Third-Quarter Net Loss
Revelation Biosciences reported a net loss of $3.3M for Q3 2026, with operating expenses rising to $3.4M from $1.9M in Q3 2025. The company has $9.1M in cash, expected to fund operations into Q2 2027. It is developing Gemini for kidney diseases and infections, with a potential $94B market according to an independent assessment.
How this was made

The 30-second read
Why it matters
The disclosed loss and cash position suggest near‑term financing risk, but the large TAM for Gemini may attract future capital.
Market read
Quarterly earnings of a micro‑cap biotech; limited broader market impact but important for niche investors.
What to watch
Potential partnership or grant funding for Gemini could improve cash runway beyond current estimates.
Background
Revelation Biosciences is a clinical‑stage biotech developing the Gemini platform for kidney‑related conditions.
Ticker impact
Revelation Biosciences disclosed its Q3 2026 net loss of $3.3M and cash runway to Q2 2027 in an 8‑K filing.
likely downward pressure as investors price in cash constraints
Quarterly loss exceeds prior year and cash balance is modest, indicating near‑term financing risk.
Market effects
Highlights funding challenges for early‑stage biotech firms developing kidney‑injury therapies.
Minimal, limited to U.S. biotech micro‑cap segment.
Low, as the company is a small cap with niche focus.
Counterpoint
If the $94B addressable market for Gemini materializes, the stock could rebound on future milestones.
Key entities
- companyRevelation Biosciences
Biotech firm developing Gemini therapy platform.